ES2062437T3 - Nueva forma farmaceutica porosa y su preparacion. - Google Patents

Nueva forma farmaceutica porosa y su preparacion.

Info

Publication number
ES2062437T3
ES2062437T3 ES90401369T ES90401369T ES2062437T3 ES 2062437 T3 ES2062437 T3 ES 2062437T3 ES 90401369 T ES90401369 T ES 90401369T ES 90401369 T ES90401369 T ES 90401369T ES 2062437 T3 ES2062437 T3 ES 2062437T3
Authority
ES
Spain
Prior art keywords
pct
preparation
pharmaceutical form
new porous
date nov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90401369T
Other languages
English (en)
Inventor
Frederic Courteille
Magali Vanhoeve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Sante SA
Original Assignee
Rhone Poulenc Sante SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sante SA filed Critical Rhone Poulenc Sante SA
Application granted granted Critical
Publication of ES2062437T3 publication Critical patent/ES2062437T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

NUEVA FORMA FARMACEUTICA LIOFILIZADA UNITARIA, POROSA DE ASPECTO HOMOGENEO, CONSTITUIDA POR: A) UN COMPUESTO DE INCLUSION QUE CONTIENE: UNO O EVENTUALMENTE VARIOS PRINCIPIOS ACTIVOS, UNA CANTIDAD PREDETERMINADA DE CICLODEXTRINA, EVENTUALMENTE UN ADITIVO QUE FACILITA LA INCLUSION; B) POR LO MENOS UNA SUSTANCIA ELEGIDA ENTRE: DILUYENTES, LIGANTES; C) EVENTUALMENTE UNO O VARIOS ADITIVOS.
ES90401369T 1989-05-24 1990-05-22 Nueva forma farmaceutica porosa y su preparacion. Expired - Lifetime ES2062437T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8906781A FR2647343B1 (fr) 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation

Publications (1)

Publication Number Publication Date
ES2062437T3 true ES2062437T3 (es) 1994-12-16

Family

ID=9381955

Family Applications (2)

Application Number Title Priority Date Filing Date
ES90401370T Expired - Lifetime ES2054289T3 (es) 1989-05-24 1990-05-22 Nuevas composiciones a base de imipramina.
ES90401369T Expired - Lifetime ES2062437T3 (es) 1989-05-24 1990-05-22 Nueva forma farmaceutica porosa y su preparacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES90401370T Expired - Lifetime ES2054289T3 (es) 1989-05-24 1990-05-22 Nuevas composiciones a base de imipramina.

Country Status (24)

Country Link
US (1) US5244881A (es)
EP (2) EP0399903B1 (es)
JP (1) JP2948271B2 (es)
KR (1) KR0163423B1 (es)
AT (2) ATE98867T1 (es)
AU (2) AU623779B2 (es)
CA (2) CA2017360A1 (es)
DD (1) DD297915A5 (es)
DE (2) DE69005359T2 (es)
DK (2) DK0399903T3 (es)
ES (2) ES2054289T3 (es)
FI (1) FI103712B1 (es)
FR (1) FR2647343B1 (es)
GR (1) GR3006655T3 (es)
IE (2) IE64370B1 (es)
IL (2) IL94460A0 (es)
NO (1) NO180517C (es)
NZ (2) NZ233766A (es)
PL (1) PL285327A1 (es)
PT (2) PT94139B (es)
TW (1) TW257672B (es)
WO (1) WO1990014089A1 (es)
YU (1) YU100790A (es)
ZA (2) ZA903895B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004318A3 (en) * 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Cyclodextrin composition
NZ246091A (en) 1991-12-24 1995-08-28 Yamanouchi Pharma Co Ltd Intrabuccally disintegrating preparation containing an active ingredient, agar, and lactose and/or mannitol
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
EP0760680A1 (en) * 1994-05-27 1997-03-12 Farmarc Nederland Bv Pharmaceutical composition
ATE421318T1 (de) * 1997-02-20 2009-02-15 Massachusetts Inst Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
TW527195B (en) 1997-10-09 2003-04-11 Ssp Co Ltd Fast-soluble solid pharmaceutical combinations
PT1052974E (pt) * 1998-02-05 2009-08-07 Novartis Ag Formulação farmacêutica contendo epotilona
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6287603B1 (en) * 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
ES2354688T3 (es) 2002-01-15 2011-03-17 Ucb Farchim S.A. Formulaciones para la administración oral de compuestos activos.
UA83341C2 (uk) 2002-02-25 2008-07-10 Дифьюжен Фармасьютикалз Ллк Біополярні солі транс-каротиноїдів та їх використання
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
DE10248314A1 (de) * 2002-10-16 2004-04-29 Dr. Suwelack Skin & Health Care Ag Verwendung von Formkörpern zur äußeren Anwendung
FR2876910B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
WO2006104610A2 (en) 2005-02-24 2006-10-05 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
EP2146948A4 (en) 2007-04-13 2010-08-04 Diffusion Pharmaceuticals Llc USE OF BIPOLAR TRANS-CAROTINOIDES AS PRE-TREATMENT AND TREATMENT OF PERIPHERAL VASCULAR DISEASE
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
EA201070544A1 (ru) 2007-10-31 2010-12-30 Диффьюжн Фармасьютикалз Ллс Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
CA2734691C (en) * 2008-09-05 2017-05-16 Mcneil-Ppc, Inc. Method for making cetirizine tablets
KR101782023B1 (ko) 2009-06-22 2017-10-23 디퓨젼 파마슈티컬즈 엘엘씨 확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도
KR101891357B1 (ko) 2010-06-02 2018-08-24 디퓨젼 파마슈티컬즈 엘엘씨 양극성 트랜스 카로티노이드의 경구용 제형
NZ608239A (en) * 2010-09-13 2015-05-29 Bev Rx Inc Aqueous drug delivery system comprising off - flavor masking agent
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
JP7032320B2 (ja) 2016-03-24 2022-03-08 ディフュージョン・ファーマシューティカルズ・エルエルシー 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5443570B2 (es) * 1972-10-27 1979-12-20
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4349472A (en) * 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4477378A (en) * 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
WO1986003198A1 (en) * 1984-11-27 1986-06-05 Dainippon Pharmaceutical Co., Ltd. 2-(1-piperazinyl)-4-substituted phenylquinoline derivatives, process for their preparation, and medicinal composition containing same
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
JP2948271B2 (ja) 1999-09-13
DE69005359T2 (de) 1994-05-05
ATE83663T1 (de) 1993-01-15
IE64370B1 (en) 1995-07-26
NO180517C (no) 1997-05-07
EP0399903B1 (fr) 1992-12-23
ES2054289T3 (es) 1994-08-01
NZ233766A (en) 1991-08-27
PT94139B (pt) 1996-12-31
KR900017570A (ko) 1990-12-19
IE901821L (en) 1990-11-24
PT94138A (pt) 1991-01-08
DK0399902T3 (da) 1994-02-14
AU5582890A (en) 1991-01-10
IL94459A (en) 1995-01-24
FR2647343A1 (fr) 1990-11-30
YU100790A (en) 1992-05-28
DK0399903T3 (da) 1993-02-08
EP0399902A1 (fr) 1990-11-28
FI103712B (fi) 1999-08-31
DE69005359D1 (de) 1994-02-03
EP0399902B1 (fr) 1993-12-22
DE69000641T2 (de) 1993-06-09
AU5743390A (en) 1990-12-18
DD297915A5 (de) 1992-01-30
CA2017360A1 (fr) 1990-11-24
JPH0356412A (ja) 1991-03-12
NZ233784A (en) 1993-04-28
PT94138B (pt) 1996-12-31
IE63317B1 (en) 1995-04-05
ZA903978B (en) 1991-03-27
FR2647343B1 (fr) 1994-05-06
FI902553A0 (fi) 1990-05-23
PL285327A1 (en) 1991-02-11
DE69000641D1 (de) 1993-02-04
IL94460A0 (en) 1991-03-10
TW257672B (es) 1995-09-21
AU623779B2 (en) 1992-05-21
ATE98867T1 (de) 1994-01-15
IE901862L (en) 1990-11-24
NO180517B (no) 1997-01-27
NO902280L (no) 1990-11-26
FI103712B1 (fi) 1999-08-31
IL94459A0 (en) 1991-03-10
WO1990014089A1 (fr) 1990-11-29
ZA903895B (en) 1991-03-27
AU631888B2 (en) 1992-12-10
CA2017355A1 (fr) 1990-11-24
EP0399903A1 (fr) 1990-11-28
US5244881A (en) 1993-09-14
PT94139A (pt) 1991-01-08
GR3006655T3 (es) 1993-06-30
NO902280D0 (no) 1990-05-23
KR0163423B1 (ko) 1998-12-01

Similar Documents

Publication Publication Date Title
ES2062437T3 (es) Nueva forma farmaceutica porosa y su preparacion.
FI901102A0 (fi) Farmaceutiska kompositioner.
FI922364A0 (fi) Farmaceutiska kompositioner.
MX9205032A (es) 1,2-dihidro-2-oxo-piridinas y procedimiento para su preparacion.
FR2705566B1 (fr) Nouvelles compositions pharmaceutiques.
MX9102580A (es) Nuevas benzodiacepinonas, procedimiento para su preparacion y composicion farmaceutica que las contiene.
DZ1559A1 (fr) Compositions pharmaceutiques.
DE59203694D1 (de) Rollstuhl, insbesondere für querschnittgelähmte menschen.
NO913035L (no) (2r)-2-(di(2-propyl)fosfonylmetoksy)-3-p-toluensulfonyloksy-1-trimetylacetoksypropan, fremgangsmaate for fremstilling og anvendelse derav.
FR2674755B1 (fr) Nouvelles compositions medicamenteuses immunostimulatrices.
ITRM920535A1 (it) Composizione farmaceutica per la somministrazione attraverso le mucose.
IT8219587A0 (it) Derivati di apovincaminolo, relativo procedimento di preparazione e composizioni farmaceutiche contenenti glistessi.
BR9107189A (pt) Tiangazol sua preparação, composições e sua itilização.
TR199500776A2 (tr) Farmasötik bilesimler.
MX9206975A (es) Composicion farmaceutica.
TR199501663A2 (tr) Farmasötik bilesimlerin hazirlanmasi icin islemler.
MX9200443A (es) Hidrato de 6-ciclohexil-2'-o-metil-adenosina, procedimiento para su preparacion y composicion farmaceutica que los contiene.
IT8920835A0 (it) Agente antitussivo e mucoregolatore, sua preparazione e composizioni farmaceutiche.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 399902

Country of ref document: ES